SCM
RARE icon

Silverarc Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Silverarc Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-124,388
Closed -$5.23M – 79
2024
Q4 		$5.23M Buy
+124,388
New +$6.17M 1.14% 31

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Silverarc Capital Management's RARE Position: Q1 2025 in Review

Silverarc Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 124,388 shares — an estimated $5.23M sold.

Silverarc Capital Management first reported a position in RARE in Q4 2024 and held it in 1 quarter. The position peaked at $5.23M in Q4 2024. 300 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • Silverarc Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 124,388 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $5.23M.
  • Silverarc Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 1 quarter.
  • Silverarc Capital Management's Ultragenyx Pharmaceutical position peaked at $5.23M in Q4 2024.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.